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Lung Infection and Immunity Unit, Division of Pulmonology and UCT Lung Institute, University of Cape Town, 7925 Cape Town, South AfricaDetection and treatment of drug-resistant tuberculosis
(TB) was not a priority in South Africa prior to 2005.
Surveillance of resistance to isoniazid, rifampicin, ethambu-
tol, and streptomycin undertaken in 2001–2002 found that
1.8% of new TB patients and 6.7% of previously treated TB
patients had multidrug resistant (MDR)-TB. Eight-percent of
strains were resistant to at least one drug and 20 (0.5%) were
resistant to all four tested drugs. The standardized treatment
adopted for MDR-TB at that time was an intensive phase of
kanamycin, ethionamide, pyrazinamide, ofloxacin, and
cycloserine or ethambutol followed by 12–18 months of
ethionamide, ofloxacin, and cycloserine or ethambutol.
Testing for resistance to second-line drugs was not routinely
undertaken. In 2005 an investigation into the unusually high
death rate among TB patients in Tugela Ferry in
KwaZulu-Natal revealed a nosocomial outbreak of extensively
drug-resistant (XDR)-TB. A death rate of over 95% was
recorded in the 1st year, including health workers at the hos-
pital. South African guidelines were reviewed and susceptibil-
ity testing for ofloxacin and amikacin was introduced in 2007
for all MDR-TB cases with capreomycin and p-aminosalicylic
acid made available for the treatment of XDR-TB.
Unfortunately, MDR cure rates remained poor and between
2007 and 2010 the number of confirmed XDR-TB cases in
South Africa rose from 458 to 741. In 2010 the MDR treatment
regimen was amended to replace ethambutol with
pyrazinamide and provide the option of replacing cycloserine
with terizidone. Standardized XDR treatment involved
capreomycin, ethionamide,p-aminosalicylic acid, moxifloxacin, and terizidone or
cycloserine. The number of XDR cases has continued to rise
as have the number of ‘‘treatment failures,” which in 2015
were estimated to comprise around 500 individuals.
Extended drug susceptibility testing is not routinely pro-
vided in South Africa but data provided by research studies
suggests high levels of resistance to second-line drugs among
patients with XDR-TB. In a prospective study in the Western
Cape of 179 newly diagnosed XDR patient isolates, 43% were
found to be resistant to at least 10 drugs. For such patients
construction of an effective regimen may not be possible
and on failing treatment they may be discharged home. In
the Western Cape study 35/104 (35%) of the home discharged
‘‘programmatically incurable” TB patients were smear posi-
tive. Whole genome sequencing identified 17 clusters of
strains or two or more patients with a difference of less than
two single nucleotide polymorphisms and identical genotypic
resistance patterns, suggesting a high likelihood of
transmission.
Access to the new drugs bedaquiline and delamanid has
been very limited in South Africa but is improving. Resistance
to these drugs is currently low. However, access to new drugs
is restricted by the need to include at least four effective drugs
in the regimen. In addition, individuals with ongoing sub-
stance abuse problems (a risk factor for drug resistance) are
considered to be unsuitable for treatment with new drugs.
Thus, a significant pool of patients with incurable TB is likely
to remain and strategies are urgently needed to prevent fur-
ther nosocomial and community-based transmission.iol. (2016),
